JP2007137842A - Nucleated tablet with bilayer shape formed by covering tablet nucleus with outer layer - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a medicine wherein a mucopolysaccharide does not interrupt the absorptance of another medically active substance in a living body. <P>SOLUTION: The medicine is a nucleated tablet with a bilayer shape formed by covering a tablet nucleus with an outer layer. The tablet nucleus comprises a mucopolysaccharide, and the outer layer comprises a medically active substance other than a mucopolysaccharide. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

  The present invention relates to a dry-coated tablet comprising a two-layer shape in which a tablet core part is enclosed by an outer layer part, and more specifically, a dry-coated tablet comprising a two-layer form comprising a lock core part enclosed by an outer layer part, The present invention relates to a dry-coated tablet containing mucopolysaccharide in the tablet core and a pharmacologically active substance excluding the mucopolysaccharide in the outer layer.

Mucopolysaccharides are known to be extremely useful for maintaining moisture in the skin, softness of the skin, skin quality, and health, and are used in many skin external preparations for the purpose of moisturizing.
Mucopolysaccharides include dermatan sulfate, chondroitin sulfate, hyaluronic acid and the like. In vivo, dermatan sulfate is bonded to hyaluronic acid together with chondroitin sulfates A and C.
Since dermatan sulfate, chondroitin sulfate A and C. hyaluronic acid are anionic molecules, they are bonded to each other to form a polymer structure and can contain a large number of water molecules. As a result, these polymer compounds are said to be able to retain moisture in the skin, and when dermatan sulfate or chondroitin sulfate is taken orally, they are taken into the body and bind to hyaluronic acid in the body to retain skin moisture. It has also been pointed out that the effect will increase.
For this reason, mucopolysaccharides are used not only as external preparations for skin but also as health foods (Patent Document 1).
In addition, taking dermatan sulfate and hyaluronic acid simultaneously orally accelerates absorption of dermatan sulfate in the small intestine, increasing absorption efficiency, improving skin age rejuvenation, and skin flexibility. It has also been reported that it has an effect to enhance, moisturize skin, increase skin metabolism, reduce fine lines, recover from fatigue, rejuvenate, relieve constipation, reduce hair removal, etc. (patent) Reference 2).

On the other hand, in addition to the mucopolysaccharides mentioned above, many pharmacologically active ingredients that have useful efficacy and are suitable for oral intake (for example, in the form of general foods, health foods, functional foods, nutrition-enriched foods, etc.) have been reported. Has been.
For example, its biosynthetic ability declines with age, and it is difficult to replenish as long as natural foods are consumed as a normal meal, even though middle-aged and elderly people want the appropriate supplementation. This includes “Coenzyme Q ₁₀ ”, which is a nutrient that is used, and “Vitamins” that are particularly difficult to supply in the present age of a stress society, as well as Coenzyme Q ₁₀ .

In addition to mucopolysaccharides, drugs containing these other pharmacologically active ingredients (coenzyme Q ₁₀ , vitamins, etc.) can be taken orally to obtain various effects and effects of mucopolysaccharides and other pharmacologically active ingredients. Is useful in that it can be obtained simultaneously.
Therefore, the tablet manufactured by adding these components (mucopolysaccharide, other pharmacologically active ingredients), mixing uniformly, and then tableting is commercially available.
However, since tablets disintegrate rapidly in the living body, a large amount of mucopolysaccharide is released into the living body in a short time. Here, in addition to the fact that mucopolysaccharide is not stable by itself and is directly denatured, it is a very viscous substance, so that it takes in other useful pharmacologically active substances such as vitamins (ie, As a result, other useful pharmacologically active substances such as vitamins could not fully exert their effects.
In addition, mucopolysaccharides are difficult to tablet because of their high viscosity.
Accordingly, development of means capable of coexisting the effects of mucopolysaccharide and other pharmacologically active ingredients has been eagerly desired.

JP-A-9-98739 JP 2005-046133 A

  The present invention has been made in view of the above circumstances (the situation surrounding the addition of nutrients in medicines, foods, etc. in which the medicinal properties of mucopolysaccharides and other pharmacologically active ingredients coexist), and the object thereof is mucopolysaccharides Another object is to provide means capable of coexisting the effects of other pharmacologically active ingredients. That is, an object of the present invention is to provide a drug capable of preventing the absorption rate of other pharmacologically active substances (coenzyme Q10, vitamins, etc.) in vivo by mucopolysaccharides.

  The present inventors have conducted various studies to develop a new type of preparation capable of coexisting the medicinal properties of mucopolysaccharide and other pharmacologically active ingredients. It has been found that pharmacologically active substances other than mucopolysaccharide can also exert pharmacological effects while having the action effect of polysaccharides, and can maintain stable quality for a long time in vivo. The present invention has been completed based on such findings.

That is, the invention according to claim 1 is a dry-coated tablet comprising a double-layered shape in which a tablet core is enclosed by an outer layer, wherein the tablet core is a mucopolysaccharide and the outer layer is a pharmacological activity other than a mucopolysaccharide. The present invention relates to a dry-coated tablet characterized by being a substance.
The invention according to claim 2 relates to the dry-coated tablet according to claim 1, wherein a space between the core tablet part and the outer layer part is coated.
The invention according to claim 3 is characterized in that the mucopolysaccharide is at least one selected from hyaluronic acid and / or a salt thereof, dermatan sulfate and / or a salt thereof, chondroitin sulfate and / or a salt thereof. It relates to the dry-coated tablet according to Item 1 or 2.
The invention according to claim 4 relates to the dry-coated tablet according to any one of claims 1 to 3, wherein the amount of the mucopolysaccharide is 0.0001 to 90% by weight.
The invention according to claim 5 is characterized in that the pharmacologically active substance other than the mucopolysaccharide is pig skin amino acid, pig skin collagen, soybean isoflavone 10, sorghum extract powder, coenzyme Q10, VB ₁ , VB ₂ , VB ₆ , crystalline cellulose, The dry-coated tablet according to any one of claims 1 to 4, wherein the tablet is one or more selected from the group consisting of sucrose esters.
The invention according to claim 6 is characterized in that the mixing ratio of the pharmacologically active substance excluding the mucopolysaccharide and the mucopolysaccharide is 0.1: 9.9 to 9.9: 0.1. The present invention relates to the dry-coated tablet according to any one of 1 to 5.

  The dry-coated tablet according to the present invention is characterized in that it has a double-layered shape containing mucopolysaccharide in the tablet core part and a pharmacologically active ingredient excluding the mucopolysaccharide in the outer layer part. Saccharides do not take up other useful pharmacologically active substances such as vitamins (ie, do not inhibit absorption), and other pharmacologically active substances such as vitamins also exert their effects as well as mucopolysaccharides. be able to.

The dry-coated tablet according to the present invention is a dry-coated tablet comprising a double-layered shape in which a tablet core part and an outer layer part are enclosed, and the mucopolysaccharide which is an organic active ingredient is contained in the tablet core part, and the mucopolysaccharide is provided in the outer layer part. A dry-coated tablet comprising an organic active ingredient excluding polysaccharides.
Hereinafter, embodiments of the present invention will be described.

The dry-coated tablet according to the present invention contains mucopolysaccharide in the tablet core.
The mucopolysaccharide used in the present invention is not particularly limited, but dermatan sulfate, hyaluronic acid, chondroitin sulfate, heparan sulfate, keratan sulfate, or salts thereof are suitable. Among them, dermatan sulfate and / or a salt thereof, hyaluronic acid and / or a salt thereof, chondroitin sulfate and / or a salt thereof are optimal.

  Dermatan sulfate is a kind of glycosaminoglycan also called chondroitin sulfate B and having a molecular weight of 2 to 400,000. In general, dermatan sulfate is mainly composed of repeating disaccharide units consisting of L-iduronic acid and N-acetylgalactosamine-4-sulfuric acid represented by the following formula 1 (chemical formula 1). The portion may be L-iduronic acid sulfate or D-glucuronic acid, a part of N-acetylgalactosamine-4-sulfate may not be sulfated, or may be 4,6-disulfated. .

  Dermatan sulfate is involved in skin fibrosis and has the effect of preventing lipoproteins (LDL and VLDL) and chylomicron vessel wall deposition, and at the epidermis level, dermatan sulfate is effective in inflammatory skin after UV B exposure. Edema action and regenerative effect have been confirmed respectively. In addition, by containing dermatan sulfate, it eliminates troubles of epidermal spinous cells, improves keratinization, and cellulitis, small hematoma, etc. due to fibrinolysis and vasodilation of dermatan sulfate It has been confirmed that it is also useful for removal.

Hyaluronic acid is a glyco having a disaccharide repeating structure of O-β-D-glucuronosyl (1 → 3) -N-acetyl-β-D-glucosaminyl (1 → 4) unit represented by the following formula 2 It is a type of saminoglycan and is mainly present in connective tissues such as joint fluids of the animals, eye glass body fluids, umbilical cords (navels), and dermis surface layers.
The molecular weight can be several hundred thousand to over two million.

  Hyaluronic acid has the effect of rejuvenating skin age, improving skin flexibility, improving skin moisture retention, improving skin metabolism, reducing skin damage caused by UV rays, and dull skin. The effect of erasing, the effect of reducing facial stains, the effect of improving makeup, the effect of reducing fine lines, the effect of applying tension around the eyes, the effect of eliminating pimples, the effect of curing dry skin, the effect of curing rough lips, It has the effect of improving the reddish face, the effect of accelerating the healing of the wound, and the effect of softening the keratin of the eyelids.

The dermatan sulfate and hyaluronic acid used in the present invention may be synthetic products, semi-synthetic products, or natural product extracts from birds, fish, mammals, and the like.
In addition, a synthetic product refers to what was manufactured by chemical synthesis, and a semi-synthetic product refers to the chemical synthesis product or what further synthesize | combined the natural product extract. When hyaluronic acid and dermatan sulfate are natural product extracts, the source of extraction is not particularly limited, but mammals that are the same as humans are preferred, and they are derived from pigs (Sus genus) that are considered to have high tissue compatibility with humans. Those are more preferred. The pig breeds include Duroc, Berkshire, Hampshire, Landrace, Large Yorkshire, Large White, and Middle Yorkshire. , Middle White) and their hybrids.

  The blending ratio of hyaluronic acid and dermatan sulfate is not particularly limited, but preferably dermatan sulfate is 0.001 to 200, preferably 0.005 to 100, with respect to hyaluronic acid 1 by weight. This is because it is considered that dermatan sulfate is not efficiently absorbed if the blending ratio of hyaluronic acid and dermatan sulfate is too different. In addition, some people have an allergic reaction and may have pimples on their skin.

Chondroitin sulfate A is a glycosaminoglycan also called chondroitin-4-sulfate, and refers to chondroitin sulfate having many sulfate groups at the 4-position.
The molecular weight is several thousand to several tens of thousands, but there are various changes in the chain length and the fine structure depending on the species, age, type of tissue, and site.
Chondroitin sulfate C is a glycosaminoglycan also called chondroitin-6-sulfate, and refers to chondroitin sulfate having many sulfate groups at the 6-position.
The molecular weight is the same as chondroitin sulfate B.
Chondroitin sulfate A and / or C to be added to the nucleated tablet of the present invention is not particularly limited, but the source of extraction is preferably the same mammal as humans, and swine (Sus) which is considered to have high tissue compatibility with humans among mammals. Those derived from the genus are more preferred.
The blending amount of chondroitin sulfate A and / or C is not particularly limited, but it is preferably about 0.001 to 100, more preferably about 0.01 to 50, and more preferably about 0.1 to 50 per hyaluronic acid weight. More preferably, about 05 to 20 is added.
This is because if the blending ratio of hyaluronic acid and chondroitin sulfate A and / or C is too different, chondroitin sulfate A and / or C will not be efficiently absorbed. In addition, some people have an allergic reaction and may have pimples on their skin.

Hyaluronic acid, dermatan sulfate, chondroitin sulfate A and C added to the dry-coated tablet of the present invention may be derived from different organisms or synthesized, but are preferably derived from the same mammal. Those derived from pigs (genus Sus), which are considered to have high tissue compatibility with humans, are more preferred.
This is because hyaluronic acid, dermatan sulfate, chondroitin sulfate A and C derived from the same organism are considered to have high intermolecular affinity, and the absorption efficiency of dermatan sulfate, chondroitin sulfate A and C via hyaluronic acid is high. Because it is considered high.

The amount of mucopolysaccharide, that is hyaluronic acid and / or dermatan sulfate, in the whole dry-coated tablet of the present invention is not particularly limited as long as it exhibits the effect as the mucopolysaccharide. About 0001 to 90% by weight, preferably about 0.001 to 80% by weight, more preferably about 0.01 to 70% by weight.
The reason for this is that if the blending amount is less than 0.0001% by weight, the effect of mucopolysaccharide itself such as moisturizing cannot be sufficiently exerted, and even if blending exceeds 90% by weight, no further effect can be expected. Therefore, in any case, it is not preferable.

The dry coated tablet according to the present invention uses the above-mentioned mucopolysaccharide as a tablet core part, a pharmacologically active substance excluding the mucopolysaccharide (mainly low molecular weight substances such as vitamins) as an outer layer part, and the tablet core part as an outer layer part. The main feature is that it is a two-layered form of inclusion (coating).
By adopting the above-mentioned shape, the pharmacologically active ingredient in the outer layer portion is released into the living body without being taken into the mucopolysaccharide and can fully exhibit its medicinal effect.
Thereafter, the mucopolysaccharide, which is the core of the tablet, is taken into the living body over time, and as a result, both the mucopolysaccharide and the pharmacologically active substance excluding the mucopolysaccharide exhibit their medicinal effects sufficiently. Will be able to.

The above-mentioned dry-coated tablet comprising the above-mentioned tablet core in an outer layer part is produced by, for example, producing a tablet core made of mucopolysaccharide as a core by a method known per se, The tablet core (press coater) can be used to coat (enclose) the tablet core with the outer shell of a pharmacologically active ingredient excluding the aforementioned mucopolysaccharides such as vitamins.
The tableting conditions at that time are not strictly limited, and can be changed according to the elution characteristics desired for the final tablet, but the tableting pressure of the core core tablet is usually about 100 to 1000 kgf. The tableting pressure of the dry-coated tablet is suitably about 500 to 2000 kgf.
Here, as long as mucopolysaccharide is contained in the tablet core, it may be only one mucopolysaccharide or may contain two or more mucopolysaccharides, other than mucopolysaccharide. It may contain other components.
In addition, the outer shell may be a single component or may contain two or more components as long as it is a pharmacologically active component other than mucopolysaccharide.
In addition, the physical shape of the whole dry coated tablet according to the present invention may be any shape such as a circular shape, a square shape, and a rugby ball shape.

The diameter of the core (tablet core) is 3.0 to 9.0 mm, preferably 4.5 to 8.0 mm, and the thickness of the core is 1.0 to 5.0 mm, preferably 1 It can be in the range of .5 to 4.0 mm.
In addition, a dry-coated tablet (bare tablet) produced by compression-coating (tableting) the outer shell portion is generally within a range of 7.0 to 13.0 mm, preferably 8.0 to 12.0 mm. The thickness can be within the range of 3.0 to 8.0 mm, preferably 4.0 to 7.0 mm.

The space between the lock core and the outer layer may be coated.
That is, the tablet core may be coated with a thin film before being covered (covered) with the outer layer. Examples of the film coating base include HPC, HPMC, hydroxyethyl cellulose, methyl hydroxyethyl cellulose, and the like. Cellulose-based water-soluble coating bases of: cellulose-based enteric coating bases such as hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, carboxymethylethylcellulose, cellulose acetate phthalate; methacrylic acid copolymers, shellac, zein, etc. It is done.

The dry-coated tablet produced as described above may be further provided with at least one light-shielding film coating on the outside after being formed into a dry-coated tablet.
Examples of such a light-shielding film coating include a cellulose-based water-soluble coating in which an appropriate amount of a light-shielding agent such as iron sesquioxide and / or titanium oxide is blended. As the cellulose-based water-soluble coating, it is preferable to use HPMC from the viewpoint of film-forming property, and HPMC having a 2% aqueous solution viscosity at 20 ° C. of 100 cp or less, particularly 15 cp or less is particularly preferable. A plasticizer such as polyethylene glycol can be added to these film coating bases as necessary.

In the dry-coated tablet according to the present invention, “pharmacologically active substance other than mucopolysaccharide” contained in the outer layer part is not particularly limited, but is mainly a low molecular weight compound such as vitamin (VB). Preferably, pig skin amino acids, pig skin collagen, soybean isoflavone 10, sorghum extract powder, coenzyme Q10, VB ₁ , VB ₂ , VB ₆ , crystalline cellulose, sucrose ester and the like can be exemplified.
These may be used alone, or any two or more selected from these groups may be used.
In the dry coated tablet according to the present invention, the blending ratio of the pharmacologically active substance excluding mucopolysaccharide and mucopolysaccharide is preferably 0.1: 9.9 to 9.9: 0.1.
Of the pharmacologically active substances, particularly Coenzyme Q ₁₀ and vitamins are known to have various effects as described later and are considered useful.

Coenzyme Q ₁₀ (CoQ · 10) is a nutrient that is considered difficult to replenish as long as natural foods are ingested as a normal meal.
Coenzyme Q ₁₀ is known as a coenzyme involved in energy production, other used as a medicament for cardiac diseases and the like, in recent years supplements, has attracted attention as a food nutritional additives.
Since CoQ · 10 has a decreased biosynthetic ability with aging, appropriate supplementation is desirable for middle-aged and elderly people. Fish, meat, seaweed, and the like are known as foods containing CoQ · 10, but the content of CoQ · 10 is extremely low in all cases. For example, in order to ingest 100 mg of CoQ · 10, 20 kg of salmon and 12 kg of broccoli are required.

Like CoQ · 10, it is difficult to replenish, and vitamins are especially essential in the modern stressed society.
Vitamin B1 (VB ₁ ) helps enzymes that break down carbohydrates and can be converted to energy. If this is insufficient, the energy metabolism of carbohydrates becomes worse, and fatigue tends to occur. Furthermore, numbness, swelling, and palpitations of limbs Symptoms such as come out.
In addition, because carbohydrates are not only the body but also the energy source of the brain and nerves, the lack of vitamin B1 can lead to loss of concentration and frustration.
Vitamin B2 (VB ₂ ) is a vitamin that works to promote cell regeneration and growth. In addition to creating healthy skin, hair, and nails, it promotes lipid metabolism and is related to carbohydrate metabolism.
When vitamin B2 is deficient, lipid metabolism does not go smoothly and it becomes difficult to become energy. Vitamin B2 also protects the mucous membrane. If deficiency occurs, stomatitis, stomatitis, redness of the eyes, keratitis, etc. Wake up.
Vitamin B6 (VB ₆ ) is a coenzyme that helps to regenerate other amino acids when there are not enough amino acids necessary for protein synthesis. If this is insufficient, protein cannot be re-synthesized sufficiently, Adversely affects maintenance.
In addition, vitamin B6 also has the effect of preventing fatty liver by promoting lipid metabolism.

Pig skin, which is said to be close to human skin, provides a rich set of amino acids.
Pig skin amino acids are efficiently absorbed from the intestinal tract of the human body and used as a basic substance for cells that make up the skin. At this time, dermal fibroblasts are used for synthesizing protein fibers such as collagen and elastin from these amino acid materials.
Therefore, pig skin amino acids and pig skin collagen are considered to be useful as “organic active ingredients excluding mucopolysaccharides” in the dry-coated tablets according to the present invention.
The present invention will be further clarified by the following examples, but the present invention is not limited to these examples.

[Example 1]
Hyaluronic acid: 25 mg, chondroitin sulfate: 25 mg, dermatanic acid: 2 mg, digestive enzyme: 5 mg, crystalline cellulose: 50 mg were mixed, and an inner core tablet with a weight of 107 mg was tableted into this. This was designated as a nuclear tablet.

Apart from this, pig skin amino acid: 100 mg, pig skin collagen: 20 mg, soybean isoflavone 10:20 mg, sorghum extract powder: 10 mg, coenzyme Q10: 10 mg, VB ₁ : 3 mg, VB ₂ : 2 mg, VB ₆ : 3 mg, crystals A total of 343 mg in which cellulose: 170 mg and sucrose ester: 5 mg were mixed was used as the outer layer part including the core tablet part.

  The core tablet part 107 mg was enclosed by the outer layer part 343 mg, and it was set as the dry tablet which consists of a total of 450 mg and a two-layer shape. This was designated as a dry-coated tablet according to the present invention. The following are examples of formulating the dry-coated tablets.

(Prescription Example 1)
Nuclear tablet part mucopolysaccharide (hyaluronic acid) 25mg
Mucopolysaccharide (chondroitin sulfate) 25mg
Mucopolysaccharide (dermatanic acid) 2mg
Digestive enzyme (metazyme) 5mg
Crystalline cellulose 50mg
107mg total
Outer layer pork skin amino acid 100mg
Pig skin collagen 20mg
Soy isoflavone 10) 20mg
Ezoukogi extract powder 10mg
Coenzyme Q10 10mg
Vitamin VB1 3mg
VB2 2mg
VB6 3mg
Crystalline cellulose 170mg
Sucrose ester 5mg
343mg total
Total: 450mg

[Example 2]
Hyaluronic acid: 20 mg, chondroitin sulfate: 20 mg, dermatanic acid: 2 mg, digestive enzyme: 4 mg, and crystalline cellulose: 40 mg were mixed, and an inner core tablet weighing 84 mg was tableted with this. This was designated as a nuclear tablet.
Apart from this, pig skin amino acid: 100 mg, pig skin collagen: 20 mg, soybean isoflavone 10:20 mg, sorghum extract powder: 10 mg, coenzyme Q10: 10 mg, VB ₁ : 3 mg, VB ₂ : 2 mg, VB ₆ : 3 mg, crystals A total of 343 mg in which cellulose: 170 mg and sucrose ester: 5 mg were mixed was used as the outer layer part including the core tablet part.
The core tablet part 84 mg was clathrated with the outer layer part 343 mg to give a total of 427 mg double-layered dry tablet. This was designated as a dry-coated tablet according to the present invention. The following are examples of formulating the dry-coated tablets.

(Prescription example 2)
Nuclear tablet part mucopolysaccharide (hyaluronic acid) 20mg
Mucopolysaccharide (chondroitin sulfate) 20mg
Mucopolysaccharide (dermatanic acid) 2mg
Digestive enzyme (metazyme) 4mg
Crystalline cellulose 40mg
84mg total
Outer layer pork skin amino acid 100mg
Pig skin collagen 20mg
Soy isoflavone 10) 20mg
Ezoukogi extract powder 10mg
Coenzyme Q10 10mg
Vitamin VB1 3mg
VB2 2mg
VB6 3mg
Crystalline cellulose 170mg
Sucrose ester 5mg
343mg total
Total: 427mg

Example 3
Hyaluronic acid: 12 mg, chondroitin sulfate: 36 mg, dermatanic acid: 4 mg, digestive enzyme: 5 mg, crystalline cellulose: 50 mg were mixed, and an inner core tablet having a weight of 107 mg was tableted into this. This was designated as a nuclear tablet.
Apart from this, pig skin amino acid: 100 mg, pig skin collagen: 20 mg, soybean isoflavone 10:20 mg, sorghum extract powder: 10 mg, coenzyme Q10: 10 mg, VB ₁ : 3 mg, VB ₂ : 2 mg, VB ₆ : 3 mg, crystals A total of 343 mg in which cellulose: 170 mg and sucrose ester: 5 mg were mixed was used as the outer layer part including the core tablet part.
The core tablet part 107 mg was enclosed by the outer layer part 343 mg, and it was set as the dry tablet which consists of a total of 450 mg and a two-layer shape. This was designated as a dry-coated tablet according to the present invention. The following are examples of formulating the dry-coated tablets.

(Prescription Example 3)
Nuclear tablet part mucopolysaccharide (hyaluronic acid) 12mg
Mucopolysaccharide (chondroitin sulfate) 36mg
Mucopolysaccharide (dermatanic acid) 4mg
Digestive enzyme (metazyme) 5mg
Crystalline cellulose 50mg
107mg total
Outer layer pork skin amino acid 100mg
Pig skin collagen 20mg
Soy isoflavone 10) 20mg
Ezoukogi extract powder 10mg
Coenzyme Q10 10mg
Vitamin VB1 3mg
VB2 2mg
VB6 3mg
Crystalline cellulose 170mg
Sucrose ester 5mg
343mg total
Total: 450mg

Claims (6)

A dry-coated tablet comprising a double-layered shape in which a tablet core is enclosed by an outer layer, wherein the tablet core is a mucopolysaccharide and the outer layer is a pharmacologically active substance other than a mucopolysaccharide. Tablets. The dry-coated tablet according to claim 1, wherein a space between the lock core and the outer layer is coated. The said mucopolysaccharide is at least one selected from hyaluronic acid and / or a salt thereof, dermatan sulfate and / or a salt thereof, chondroitin sulfate and / or a salt thereof. Nuclear tablet. The dry-coated tablet according to any one of claims 1 to 3, wherein the amount of the mucopolysaccharide is 0.0001 to 90% by weight. The pharmacologically active substance other than the mucopolysaccharide is selected from the group consisting of pork skin amino acids, pork skin collagen, soybean isoflavone 10, sorghum extract powder, coenzyme Q10, VB ₁ , VB ₂ , VB ₆ , crystalline cellulose, and sucrose ester. The dry-coated tablet according to any one of claims 1 to 4, wherein the dry-coated tablet is any one or more of the above. The blending ratio of the pharmacologically active substance excluding the mucopolysaccharide and the mucopolysaccharide is 0.1: 9.9 to 9.9: 0.1, according to any one of claims 1 to 5. Nucleated tablets.